Focused on developing antiviral therapies, this biopharmaceutical company specializes in treatments for RNA viruses including COVID-19 and hepatitis C. Investors monitor its clinical-stage pipeline and partnerships with larger pharma companies for commercialization.
1 member of Congress has disclosed 1 trade in Atea ASA (ATAZF), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-09-28 | MICHAEL K. SIMPSON | sell | $1K – $15K |